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Molecular alterations in the prostate cancer proteome mediate the functional and phenotypic transformation from clinically localised
to metastatic cancer, a transition that drives patient’s mortality and challenges therapeutic intervention. A first approximation of
differential proteomic alterations stratified by disease stage has yielded repertoires of potential diagnostic and prognostic markers,
multiplex signatures of predictive value, and yield fundamental insight into molecular commonalities in cancer progression.
Deciphering these causative proteomic alterations from the molecular noise will continue to mature our understanding of tumour
biology and drive new computational and integrative approaches to model a system’s view that accommodates the heterogeneity of
prostate cancer progression.
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Although clinically localised prostate cancer can be treated with
androgen ablation, surgical resection or radiation, its transition to
metastatic disease is almost uniformly fatal. Understanding the
molecular hallmarks of this transition has been the target of
extensive study by the wider research community. In this context,
a multitude of both diagnostic and prognostic tissue and serum
biomarkers have been proffered as viable supplements to the
standard clinical parameters in use now. These include prostate-
specific antigen, Gleason score and clinical stage; however, these
are individually opaque to sensitive disease fate decisions. In
parallel, there are emerging efforts in integrative and systems
approaches to prostate cancer progression. These promise not only
molecular profiles and signatures, but also models of progression
that assimilate the heterogeneity and complexity of a decidedly
continuous and nonlinear biological process. We focus here on
recent approaches and discoveries, and specifically in the context
of those proteomic alterations between the later, progressive stages
of prostate cancer.
DISCOVERY AND DIVERSITY OF ALTERATION
TYPES AND A VECTOR OF PROTEOMIC CHANGE
The explosion of high-throughput platforms for protein-level
analysis, primarily driven by mass spectrometry and array-based
methodologies, represents a transition to an exponential phase in
oncoproteomics. The biomedical literature is replete with prostate
cancer profiling efforts and biomarker discovery in serum, urine,
and a growing number in tissue along with variations on early
detection platforms and technologies (Wulfkuhle et al, 2003).
Many of these are exploiting the more immediate translational
opportunities in clinical proteomics. These include biofluid
profiling, despite the challenges of reproducibility from physiolo-
gical variability. As our focus here is on proteomic alterations in
the prostate cancer tissue proteome, we benefit from circumvent-
ing the many problems of secondary and tertiary clinical
conditions that drive this physiological variation between and
among patient cohorts. Alternatives exist to these explicit and
discrete protein biomarker identification techniques. One such
method is SELDI-TOF-derived proteomic pattern diagnostics
coupled to both significant bioinformatics and up- and down-
stream sample processing. Nevertheless, much of the existing work
across all sample classes confirms a confounding paradox in the
cancer proteomics community. Although the vast majority of FDA-
approved biomarkers are indeed proteins, none were discovered
via high-throughput experimentation and few are used in routine
clinical practice (Ludwig and Weinstein, 2005). Consequently,
work of our group and others focuses on satisfying the twin and
overlapping goals of viable biomarker discovery and deconvolut-
ing the proteomic mechanisms in prostate cancer progression.
During the stages of cancer progression, the tissue proteome
fluctuates exquisitely reflecting a dynamism fundamental to the
complexity of the process. It is a constantly moving target, the
combination of changes that span a vast array of both physical and
functional modifications, as well as proteins being secreted and
culled from the circulating proteome or degraded by deregulated
proteolytic processes. Modifications include differential expression
and protein coexpression, most frequently quantified in clinical
samples with chemically incorporated stable isotope labelling
coupled to high mass accuracy mass spectrometry. Another is
altered localisation characterised by the direct analysis of tissue
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(IMS) (Caprioli, 2005). Other changes include modifications to
networks of protein–protein interactions mediating nearly all of
the molecular events in disease progression, which are amenable to
protein microarray analysis. Additionally, and playing a pivotal
functional role in oncogenesis and progression, are post-transla-
tional modifications, which require platforms of high mass
accuracy and increasing levels of sensitivity for high-throughput
discovery. Finally, it is worth mentioning the effect that isolation
and extraction techniques, such as laser-capture microdissection
(LCM), are having on the known altered proteome in prostate
tissue, whether clinically localised or metastatic disease.
Althoughly this method aids immeasurably in generating homo-
genous tumour cell populations for study and certainly improves
the specificity of electrophoretic methods like 2D-PAGE in
biomarker discovery, it may also help unmask critical alterations
otherwise unavailable at the whole-tissue level. The tumour
microenvironment is a heterogeneous mix of cell types that
includes stromal constituents. In lieu of pure epithelial cell models,
LCM in combination with better computational tools is helping to
sift out functionally contributing stromal proteins from those that
are truly contamination. This will capture a more complete picture
of the proteomic interplay in the tumour microenvironment that
includes potentially important stromal components. Together,
these technologies are generating individual and combinations of
proteomic targets.
Although rigid protein repertoires generated from these plat-
forms are informative, they are single dimensional. As a result,
their sufficiency is subordinate to otherwise factorial molecular
behaviour. Much of the newest proteomic profiling work is
generating steady-state first approximations of the differential
proteome between discrete stages of prostate cancer (Varambally
et al, 2005). Furthermore, this work represents an analytical shift
towards integrative molecular study, a systems approach to
dissecting the molecular events that dictate prostate cancer
progression. In this context, there are significant qualitative
changes happening both locally and globally at the proteomic
level, independent of any single protein, which might be thought of
as gross proteomic remodelling between disease stages.
Our group and others have observed, via high-throughput tissue
microarray analysis, a general vector of qualitative change at the
protein level between clinically localised and metastatic tissue
extracts. Leveraging immunohistochemically compatible antibo-
dies, and aside from differences in individual alterations, we are
witnessing broader trends in epithelial cell staining paralleling
discrete transitions in progressive disease (Varambally et al, 2005).
This includes metastatic tumours showing reduced membranous
staining as compared to localised tumours, which might be
predicted by canonical models of adhesion, invasion and
proteolytic degradation. Further, these may become increasingly
accessible to characterisation as methods for mass spectrometry-
based membrane proteomics improve (Wu and Yates, 2003).
Additionally, cellular conflation and tumour composition also
affect proteomic behaviour, which is uncovered in subsequent
staining. This is attributable to factors including the increase in
density of tumour cells potentiating higher protein expression
levels in localised and metastatic prostate cancer, as well as shifts
in stromal to epithelial components between disease stages.
Tumours also demonstrate variable levels of subcellular and,
especially, nuclear protein expression across a range of markers,
which may again be a product of cellular density and not
necessarily a direct product of tumour progression. These high-
er-level observations purport a holistic approach to tissue
proteome analysis. Vertically integrating between the depths of
analysis in individual protein alterations to the higher-level
breadth of gross behavioural observations allows for larger and
more comprehensive models of the prostate cancer tissue
proteome.
ALTERATIONS IN A GLOBAL PROGRESSION
SIGNATURE
There is currently a relative paucity of work on profiling proteomic
alterations in tissues between the various disease stages in prostate
cancer. This is more often dealt with at the transcriptomic level
(Stanbrough et al, 2006), from which the vast majority of existing
prostate cancer markers, prognostic or otherwise, have been
characterised. However, the newest parallel efforts in systematic
protein analysis are further elucidating the behaviour of these and
many more, of which we have sampled a small fraction (Table 1). A
portion of these is extensively well-studied and fundamentally
archetypal of high-throughput profiling for disease markers and
are well-reviewed elsewhere (Kumar-Sinha and Chinnaiyan, 2003).
Nevertheless, we spend some time here discussing a subset of
these; a transcriptional repressor, enzyme, kinase and two nuclear
Table 1 Limited sampling of protein alterations in clinically localised prostate cancer relative to benign prostate and metastatic prostate cancer relative to
clinically localised
Alteration
Localised prostate cancer Metastatic prostate cancer
Locus Protein (mRNA) Protein (mRNA) Prognostic Reference
AMACR (
a) k (k
a) Y|N Rubin et al (2002)
HEPSIN (
a) k (k
a) — Dhanasekaran et al (2001)
EZH2 3 (m) ( ) Y Varambally et al (2002)
JAGGED1 m (m
a) (
a) — Santagata et al (2004)
XIAP m (m) m (3)— D a n et al (2004)
STK15 3 (m) (m) Y Jeng et al (2004)
MET (k
a) (k
a) N Watanabe et al (1999)
pPKR —
b (—) k
c (—) — Jammi and Beal (2001)
ICBP90 3 (3) m (m) — Hopfner et al (2000)
BM28 m (3) m (m) Y Meng et al (2001)
MSH2 m (m) m (m) — Velasco et al (2002)
UBC9 m (3) (
a) — Poukka et al (1999)
Arrows and weights reflect directionality and degree of change in protein expression. mRNA transcript expression is included as a reference and to emphasise the multi-
dimensionality of integrative analysis of protein alterations. Additional annotations include the superscript.
aFor oncomine-derived expression across multiple prostate cancer
profiling studies (Rhodes et al, 2004).
bRepresents phosphorylation.
cRepresents post-translational modifications of any kind.
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proteomic alterations between stages of prostate cancer. Addition-
ally, that all of these were discovered or recapitulated by our
laboratory’s recent work with a single high-throughput immuno-
blot approach emphasises the capacity of new experimental and
integrative approaches to model large swaths of the differential
prostate cancer proteome (Varambally et al, 2005).
The first of these proteins is EZH2, the human homologue of the
Drosophila protein Enhancer of Zeste (E(Z)), a member of the
Polycomb group of proteins. It is involved in epigenetic gene
silencing. Recently, it has been linked via DNA methyltransferases,
suggesting a direct connection between two key epigenetic
repression systems (Vire et al, 2006). Our group evaluated the
expression of EZH2 by immunohistochemistry using tissue
microarrays from patients with either clinically localised or
hormone-refractory prostate cancer. The result indicated poorer
prognosis with increased EZH2-positive staining and suggests
prostate cancer progression and metastasis with increased EZH2
expression (Varambally et al, 2002). In addition to prostate cancer,
we have demonstrated that EZH2 protein levels were strongly
correlated with breast cancer aggressiveness and promote
neoplastic transformation of breast epithelial cells (Kleer et al,
2003). We have also shown that EZH2 promotes anchorage-
independent growth and cell invasion and endows primary
cells with a proliferative advantage. Additionally, its gene locus
is specifically amplified in several primary tumours (Sudo et al,
2005; Bachmann et al, 2006). Importantly, studies have demon-
strated the intrinsic enzymatic activity of EZH2 as a histone H3
lysine 27 methyltransferase, which is critical to its function as a
transcriptional repressor and oncogene (Cao and Zhang, 2004).
Thus, if a small molecule inhibitor can be identified against EZH2
enzymatic activity or its protein–protein interactions, this may
have utility as a viable therapeutic against tumours expressing
high levels of EZH2. Based on the early success of HDAC
inhibitors, we expect that targeting EZH2 may be a more specific
and rational therapy.
Another protein, alpha-methylacyl-CoA racemase (AMACR), is
a peroxisomal and mitochondrial enzyme involved in the b-
oxidation of branched fatty acids. It was discovered to have
specifically increased expression in prostate cancer epithelia
(Rubin et al, 2002). Our studies have also demonstrated that
AMACR enzymatic activity is increased in prostate cancer relative
to benign epithelia (Figure 1) (Kumar-Sinha et al, 2004). Of
particular interest, we have identified a humoral immune response
against this enzyme in prostate cancer patient serum (Sreekumar
et al, 2004). Furthermore, we have shown that AMACR expression
is highest in localised prostate cancer and decreases in metastatic
disease, and subsequent reductions in AMACR expression in the
former is associated with an increased rate of biochemical
recurrence (Rubin et al, 2005). Although this reduction in
hormone-refractory metastasis has been repeatedly observed, little
correlation between it and other clinical parameters exists in
prostate cancer progression. Additionally, its independence of
androgen receptor-mediated signalling has spawned associations
between AMACR protein expression loss and tumour dediffer-
entiation, and the latter’s appropriation of pathway control to
maintain the formers enzymatic and energy regulation activity.
Aside from these observations, a causal link between AMACR
protein expression patterns and prostate carcinogenesis is yet to be
elucidated.
On the other hand, the centrosome-associated oncogenic kinase
Aurora-A, or STK15, belongs to a family of serine/threonine
kinases. It has been implicated in playing a crucial role in the
control of mitosis. Overexpression of STK15 results in chromoso-
mal aberration, genomic instability and tumorigenesis. This kinase
is also known to be amplified in a number of human cancers and
tumour cell lines (Jeng et al, 2004). STK15 was also shown to
regulate the p53 pathway by inducing increased degradation of
p53, leading to aberrant checkpoint responses and facilitating
oncogenic transformation of cells (Katayama et al, 2004). It also
plays a key role in G2/M-phase progression. Studies demonstrated
that STK15 also provides drug resistance, and inhibiting its
expression by RNA interference can result in potent sensitisation
to the chemotherapeutic Taxol in human cancer cells (Hata et al,
2005). Our proteomic screen showed a marked upregulation of this
kinase in metastatic prostate tumours.
Another protein, MSH2, is encoded for by a gene that is a
member of a family of genes long implicated in oncogenesis, and
specifically hereditary and sporadic colorectal carcinomas. The
gene functions in mismatch recognition during the repair of errors
occurring during DNA replication. Identified germ-line missense
mutations are known to contribute to the onset of HNPCC, and the
gene was shown to be upregulated in primary prostate cancer
(Velasco et al, 2002), a result concordant with its protein
expression in our screen. The same study also demonstrated that
MSH2 expression in prostate carcinoma may be a useful
prognostic marker for outcome in men with clinically organ-
confined prostate carcinoma.
Finally, BM28, whose alias is MCM2, is a well-characterised
mini-chromosome maintenance protein, and is known to play an
essential role in initiation and regulation of eukaryotic DNA
replication. It has been shown to be dysregulated in malignant
prostate glands (Meng et al, 2001). The same study also suggested
that BM28 expression is an independent predictor of disease-free
survival after definitive local therapy, and has potential as a
molecular marker for clinical outcome in prostate cancer.
These five either established or putative proteomic alterations in
prostate cancer only partially reflect a true diversity of function
that reaffirms its molecular heterogeneity. Nonetheless, much
remains to be performed both experimentally and bioinformati-
cally for these and many more in pathway enrichment, identifying
functional targets, regulatory relationships and protein–protein
interaction sub-networks to properly contextualise these
entities and understand their contribution to prostate cancer
progression.
PROVIDING FUNCTIONAL CONTEXT TO
ALTERATIONS
The molecular profiling of prostate cancer tissue for proteomic
alterations has certainly advanced the list of targets potentially
mediating the neoplastic phenotype and aggressive subtypes.
However, systematic biological contextualisation has lagged their
initial discovery. This might be expected as a result of labour-
intensive experimental characterisation for single proteins, but this
also requires mining and computational approaches that can better
AMACR
Figure 1 Prostate cancer tissue staining for AMACR. High levels of the
prostate cancer biomarker AMACR (green) stained mainly in clinically
localised prostate cancer glands compared with internal adjacent benign
glands. A higher magnification image is included on the right, and
membrane E-cadherin expression is shown in red.
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corollary data types, much like those developed for the gene
expression domain.
An effective repository and analytical platform providing meta-
analysis of proteomic alterations in patient material paralleling the
successful efforts in cancer microarray analysis would greatly
benefit the cancer proteomics community (Rhodes et al, 2004).
The task of useful integration and compendium development is
complicated by the dimensionality and diversity of proteomic data
as previously discussed, which is a more tractable problem in the
DNA microarray domain. Despite distinct experimental platforms,
DNA microarrays generate uniformly single-dimensional, semi-
quantitative molecular abundance data. However, proteomic data
are decidedly higher dimensional, whose diversity of data type
includes quantitative, nominal, categorical, binary and more.
Nevertheless, the benefits of such a compendium-based meta-
analysis at the protein level, a platform that systematises and
integrates diverse protein data from the public domain, are many-
fold. They include functional enrichment for biological processes,
molecular function, and pathway membership. Another is map-
ping to existing protein–protein interaction data, and integration
for targets of existing therapeutics and small-molecule inhibitor
libraries to suggest altered combinatorial therapies at the protein
level. Others include integration with antibody repositories, and of
course with gene expression data, helping the community better
understand the regulatory processes mediating the relative
discordance witnessed between the two observed in small scale
in previous studies.
We foresee such a platform addressing a variety of current
complications in extracting truly causal proteomic alterations from
larger, noisy data sets. We briefly identify several problems that
would be aided by such an analytical approach. First, and
particularly problematic, are those stochastic events that are
consequences of the neoplastic phenotype as opposed to
determinants of it. Filtering for putative alterations in prostate
cancer pathogenesis may begin with altered protein expression,
but much like at the transcriptome level, this must be qualified and
validated.
A second problem is that of tissue specificity, sample selection
and annotation. Certainly one of the primary considerations in this
context is how to deal with protein markers having tissue
specificity. This trait is indicative of the physiological site of
metastatic sample analysed, and is indicative only of the latest
stages of secondary-site micro- and macro-metastases and perhaps
not causal in progression to metastatic disease. Better bioinfor-
matic tools are required to either properly classify these or
subtract them from a causal compendium. Such an analytical
platform for comparative analysis across large proteomic data sets
culled from a variety of distal sites to the primary site of disease
will allow for easier assessment of tissue-specific proteomic noise.
A third important distinction to be made is between those
protein markers having utility in a prognostic signature and those
with actual biological relevance to the disease state, as these are
certainly not mutually inclusive. Correlations between entities, be
they genes in a transcriptomic signature, or proteins in proteomic
ensemble, may drive the value of a given prognostic signature and
a priori outcome determination, but do not equate to fundamental
biological interactions, whether regulatory, binding, kinetic or
otherwise. These artefacts are often the consequence of a variety of
statistical learning implementations that range from ‘black box’,
which masks the structure of the data, to the relatively transparent
from which rules can be read with relative ease. However,
discriminating between statistical vs biological significance re-
mains a fundamental challenge even with the increasing complex-
ity and sophistication of these analytical approaches.
Many of these complications in generating biological context for
proteomic alterations implicated in prostate cancer progression
are being addressed through smaller-scale integrative approaches
that correlate transcriptomic and proteomic experimental data,
mine publicly available data sets, and add dimensionality through
the inclusion of molecular interaction data. Integrative biology of
this type is paradigmatic of a movement towards a systems biology
framework that was previously unavailable to biomedical research
(Hood et al, 2004). We foresee that such a compendium for
widespread analysis will facilitate these types of analyses on a far
larger scale.
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Figure 2 Overview of the conceptual flow in characterising proteomic alterations between prostate cancer stages. Starting from a diverse sample
population, a vast array of sample preparation methods and high-throughput technologies can be leveraged to differentially profile tissue stratified by disease
progression. A variety of resulting data types, formats, and dimensionality require significant integration and bioinformatic analyses to tease causal entities
from the molecular noise and agglomerate the results into one of many desired outcome models motivated by study design.
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As technologies and analytical approaches to prostate cancer
profiling mature, so will the compendium of proteomic alterations
between stages of disease. However, the contextualisation of these
molecular determinants in the biology of cancer progression is
fundamental to our understanding of their role in the acquisition
of phenotypic hallmarks of individual disease. While complex in
implementation and variable in capacity for different sample types,
high-throughput technologies being used today are key to this
effort. Platforms include mass spectrometry and its corollary
sample reduction methods, high-throughput immunoblots, tissue
microarrays, and protein microarrays. The latter includes reverse-
phase implementations, antibody arrays, phage display or others
in profiling of serum, amplified immune response and others
(Figure 2). This broad sampling of platforms is aiding the
characterisation of causative alterations at the protein level that
are otherwise masked by the molecular noise or lost to
physiological variability. However, these are only tools, and their
utility must be informed by a comprehensive understanding of the
heterogeneous nature of prostate cancer. In larger profiling
studies, end-stage metastatic prostate cancer is often aggregated
as a single class of disease; however, diverse metastases
demonstrate significant heterogeneity, distal organ specificity,
and at the molecular level, equate to distinct subtypes of hormone-
refractory prostate cancer (Shah et al, 2004). An appreciation
for this composition of metastatic disease must filter down to
the study of proteomic alterations, not simply stratified by
progression through discrete disease stages, but also within-stage
subtypes. This approach promises an alternative to end-point
analysis, rather a dynamic proteomic model of progression to
metastatic prostate cancer, a combinatorial ensemble suitable for
efforts ranging from quantitative modelling to therapeutic
perturbation.
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